IMBRAVE-151, A Phase II, Randomized, Double-Blind Placebo-Controlled Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer, shared by Dr. Ghassan Abou-Alfa of Memorial Sloan Kettering Cancer Center.